Biologic Drugs Challenge the Biopharma Industry

Media Coverage
Image of cells under a microscope.

PharmTech

Advances in biologic drug development require increased methodological and technological innovation from the biopharma industry. In an interview with Mark Emalfarb, CEO of Dyadic International, a biotechnology company focused on developing biologic vaccines and biologic drugs, and Mario DiPaola, PhD, senior scientific director at contract research organization Charles River Laboratories, Pharmaceutical Technology explored how to create better biologic building blocks to help minimize the pressure placed on the industry by current development cost and time-to-market challenges.

Read the Full Article